AI Therapeutics has launched a Phase 2 clinical trial into AIT-101 (apilimod dimesylate) as a potential oral treatment for amyotrophic lateral sclerosis (ALS) associated with C9orf72 mutations. The trial (NCT05163886) is currently recruiting at the Massachusetts General Hospital and is expected to soon open at sites in…
News
Amyotrophic lateral sclerosis (ALS) can be grouped into four disease subtypes based on patterns of changes in electrical signals in the brain, researchers have discovered. These findings may be valuable to predict future disability and life expectancy, and may help select the patients more likely to benefit in certain…
Note: This story was updated Jan. 25, 2022, to clarify that Target ALS has raised $90 million since its inception in 2010. Amyotrophic lateral sclerosis (ALS) has been a part of Daniel Doctoroff’s life for more than two decades. His father, Martin Doctoroff, died of the disease in 2002, and…
Ady Barkan was a new father and activist when, at age 32, he learned that he had amyotrophic lateral sclerosis (ALS). His ensuing fight for universal healthcare while dealing with the progressive neurodegenerative disease is at the center of “Not Going Quietly,” a film debuting on PBS today,…
Amarna Therapeutics and Redoxis have received an €800,000 (about $900,000) grant from Eureka Eurostars to advance their joint project, ALPHAVAC, which aims to discover immune-related therapeutic targets of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Promising targets, initially focused on ALS, then will be used to…
The French health authority ANSM has approved InFlectis BioScience’s request to launch a Phase 2 clinical trial testing its lead candidate IFB-088, in combination with riluzole, in people with bulbar-onset amyotrophic lateral sclerosis (ALS). The trial is expected to be conducted in France and Italy, and a similar request is being…
Urine levels of neopterin, a marker of inflammation, are linked to disease progression in people with amyotrophic lateral sclerosis (ALS), a study revealed. That means, according to researchers, that neopterin could be used as a biomarker to monitor disease status and determine whether certain treatments will be effective. The…
The U.S. Food and Drug Administration (FDA) has approved a Phase 2 clinical trial of the psychedelic ketamine, PharmaTher’s experimental treatment for amyotrophic lateral sclerosis (ALS). FDA approval was requested through an investigational new drug application (IND) submitted by the study’s principal investigator, Richard Barohn, MD, a neurologist…
The National Institute of Neurological Disorders and Stroke (NINDS) is asking people across the amyotrophic lateral sclerosis (ALS) community to submit their preferences regarding what should be prioritized to accelerate ALS research. NINDS, which is part of the National Institutes of Health (NIH), is seeking contributions from ALS patients,…
AcuraStem’s experimental therapy AS-202 significantly reduced neurodegeneration and improved motor function and survival in a mouse model of aggressive amyotrophic lateral sclerosis (ALS) associated with toxic clumps of the TDP-43 protein, the company announced. Preclinical studies also confirmed the therapy’s biological activity and target engagement and suggested that…
Recent Posts
- Trial testing new ALS gene therapy starts dosing patients in Australia
- In life with ALS, we find moments of ‘genius’ to keep our minds active
- Brain imaging agent shows promise for detecting toxic ALS protein
- I reframed my life with ALS by becoming a calmer duck
- New ALS treatment improves survival, leads to function gains in trial